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Aims: To investigate, for a given energy expenditure (EE) rise, the differential effects of glucagon infusion and cold exposure on brown adipose tissue
(BAT) activation in humans.
Methods: Indirect calorimetry and supraclavicular thermography was performed in 11 healthymale volunteers before and after: cold exposure; glucagon
infusion (at 23 ∘C); and vehicle infusion (at 23 ∘C). All volunteers underwent 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT
scanning with cold exposure. Subjects with cold-induced BAT activation on 18F-FDG PET/CT (n= 8) underwent a randomly allocated second 18F-FDG
PET/CT scan (at 23 ∘C), either with glucagon infusion (n= 4) or vehicle infusion (n= 4).
Results: We observed that EE increased by 14% after cold exposure and by 15% after glucagon infusion (50 ng/kg/min; p< 0.05 vs control for both). Cold
exposure produced an increase in neck temperature (+0.44 ∘C; p< 0.001 vs control), but glucagon infusion did not alter neck temperature. In subjects
with a cold-induced increase in the metabolic activity of supraclavicular BAT on 18F-FDG PET/CT, a significant rise in the metabolic activity of BAT after
glucagon infusion was not detected. Cold exposure increased sympathetic activation, as measured by circulating norepinephrine levels, but glucagon
infusion did not.
Conclusions: Glucagon increases EE by a similar magnitude compared with cold activation, but independently of BAT thermogenesis. This finding is of
importance for the development of safe treatments for obesity through upregulation of EE.
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Introduction
Obesity results from an excess of caloric intake relative to
energy expenditure (EE). There are now 600 million adults
who are obese [bodymass index (BMI)>30 kg/m2] worldwide.
Obesity is causally linked to the development of type 2 diabetes,
cardiovascular disease, some cancers [1] and early mortality.
Lifestyle strategies for weight loss are based on calorie restric-
tion, alongside increasing EE via exercise, but these efforts are
difficult to sustain in the long term. Currently licensed drugs,
generally aimed at either reducing intestinal fat absorption
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(such as intestinal lipase inhibitors) or inhibiting appetite (such
as phentermine), have limited weight loss efficacy on their
own. Anti-obesity agents which elevate EE by stimulating the
sympathetic nervous system have produced dangerous side
effects, particularly cardiovascular morbidity [2–4]. There is a
great unmet need for drugs that can safely inhibit appetite and
increase EE.
One possible solution is a pharmacological agent that acts
as a co-agonist of both glucagon-like peptide-1 (GLP-1) and
glucagon receptors, harnessing the anorectic and glucose-
lowering effects of the former with increased EE via the lat-
ter [5,6]. Glucagon infusion acutely increases EE in humans
[7,8], but the mechanism by which this occurs is not known.
Rodents can increase their EE via activation of brown adi-
pose tissue (BAT), which consumes fuel for thermogenesis
using uncoupling protein-1 (UCP-1), and do so in response
to both cold exposure and caloric excess [9]. UCP-1-positive
BAT deposits that can be activated by a variety of stimuli,
most potently cold exposure, have been recently described
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in adult humans, particularly in the supraclavicular neck
region [10–12].
Isolated brown fat cells from rats have been shown to respond
thermogenically to glucagon [13] and glucagon administra-
tion to rodents increases BATmass and activity [14]. Glucagon
knockout mice have reduced thermogenic responses to cold
exposure and pharmacological adrenergic stimulation, which
is restored by glucagon replacement [15], although the partici-
pation of BAT in the thermogenic response to glucagon admin-
istration is not firmly established [16]; therefore, glucagon may
increase EE in humans via activation of BAT, but studies inves-
tigating this are lacking.
We carried out a series of experiments to investigate, for
the first time, whether the increased EE resulting from acute
glucagon administration was mediated by BAT activation in
adult humans.
Materials and Methods
Subjects
A total of 11 healthy men (mean age 26.1 years, range
20.8–39.8 years, mean BMI 22.5 kg/m2, range 20.5–25.2 kg/m2)
were recruited through advertisement and assessed as healthy
during a screening visit with a medical history, routine blood
tests and ECG. Exclusion criteria were smoking, substance
abuse, eating disorders, regular medication and medical or
psychiatric illness.The study was approved by the LondonCen-
tral Ethics and Research Committee (13/LO/0925), registered
with ClinicalTrials.gov (NCT01935791) and performed in
accordance with the Declaration of Helsinki. Informed consent
was obtained from subjects before enrolment in the study.
Study Visits
Cold exposure and glucagon infusion have both been shown
to acutely elevate EE in humans but have never been directly
compared in the same cohort. We performed this compari-
son in 11 healthy young men. Each subject underwent mea-
surement of resting metabolic rate (RMR) using an indirect
calorimeter (Gas Exchange Monitor; GEM Nutrition, Dares-
bury, UK) at the start and end of three separate interventions:
cold exposure, glucagon infusion in a warm room and vehi-
cle infusion in a warm room. During these visits, we also used
infra-red thermography of the neck, which has recently been
reported to be a reliable method of measuring BAT thermo-
genesis [17,18]. The calorimetry/thermal imaging visits were
randomly assigned and are summarized below:
• Calorimetry and thermal imaging wearing a cooling vest
(Polar Products®, Stow, OH, USA) [19] with a 55-min intra-
venous (i.v.) vehicle (Gelofusine®; B. Braun, Sheffield, UK)
infusion (cold visit).
• Calorimetry and thermal imaging in a warm room (ambient
temperature 22–25 ∘C) with a 55-min i.v. vehicle infusion
(control, vehicle visit).
• Calorimetry and thermal imaging in a warm room (ambi-
ent temperature 22–25 ∘C) with a 55-min i.v. glucagon infu-
sion at 50 ng/kg/min (NovoNordisk, Gatwick, UK; glucagon
visit).
18F-fluorodeoxyglucose (18F-FDG) positron emission
tomography (PET)/CT scanning is the most widely accepted
method of identifying metabolically active BAT. All 11 subjects
attended an initial ‘cold’ 18F-FDG PET/CT scan study visit
(described below), to ascertain if they were BAT-positive or
BAT-negative.
Eight of the 11 subjects were confirmed as having supra-
clavicular BAT deposits on their initial 18F-FDG PET/CT scan,
based on standardized uptake value (SUV) characteristics
previously defined [20]. This BAT-positive cohort then partici-
pated in a 5th study day, when a second 18F-FDG PET/CT scan
was performed, randomized to either: 18F-FDG PET/CT with
a 55-min glucagon infusion at 50 ng/kg/min at 23 ∘C (n= 4)
or 18F-FDG PET/CT with a 55-min vehicle infusion at 23 ∘C
(n= 4).
The study design is summarized in Figure 1 and timelines
are detailed in Figure S1A–C. Subjects fasted and drank only
water from 22:00 hours the night before each study visit. They
ate the same meals the day before every study visit, abstained
from alcohol, caffeine and avoided strenuous exercise for 24 h
before each visit. Each visit was separated by at least 3 days. On
arrival, peripheral venous cannulae were inserted in both fore-
arms (one for infusion and one for blood sampling). Volunteers
were blinded to the contents of the i.v. infusions. RMRwasmea-
sured at the start and end of each thermal imaging visit using an
indirect calorimeter (Gas Exchange Monitor; GEM Nutrition).
At the start of each study visit the calorimeter was calibrated
with ‘zero’ (0.00% O2 and 0.00% CO2) and ‘span’ (20.00% O2
and 1.00%CO2) gases (BOC,Guildford, UK).Human glucagon
was purchased from Novo Nordisk (UK); 1mg was diluted
into 50ml Gelofusine and the flow rate through the Alaris®
syringe pump was adjusted to a maintenance i.v. delivery rate
of 50 ng/kg/min.This dose was chosen based on previous work
in our department to produce an acute rise in EE compara-
ble with other studies examining the effects of cold exposure
on EE and BAT activity [21]. To ensure plateau plasma lev-
els were quickly attained when glucagon was delivered, infu-
sions were ramped at 4× maintenance rate (MR) for the first
5min, 2×MR for the next 5min and 1×MR for the remain-
der of the 55-min infusion. The Polar Products cooling vest
used in this experiment has been previously confirmed to suc-
cessfully induce cold-activated BAT without needing to change
the ambient temperature of the experimental room [19]. The
waistcoat-shaped vest was worn by the participants directly
over a thin cotton hospital gown. Cold water (maintained at
8 ∘C by attaching to a temperature-controlled tank) was con-
tinuously pumped through the vest. The subjects felt cold but
none of them reported (or were observed to be) shivering (this
was checked every 15 min).
Thermal Imaging Protocol
Volunteers wore a pair of light cotton trousers only. On the
cold visit day the cooling jacket was wrapped around the vol-
unteer’s torso leaving the supraclavicular regions uncovered.
After a 30-min acclimation period, baseline thermal images
were recorded for 10min using a Flir T440bx infrared camera
(Flir Systems, West Malling, UK) mounted on a tripod placed
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30 screened
N=8 BAT positive then 
randomised to:
18F-FDG PET/CT scan in warm 
room with vehicle infusion
OR
18F-FDG PET/CT scan in warm 
room with glucagon infusion
11 eligible and able to 
complete all study visits
All 11 underwent:
18F-FDG PET/CT scan with 
cooling vest and vehicle 
infusion
All 11 underwent:
1.  Calorimetry and thermal 
imaging with cooling vest and 
vehicle infusion
2.  Calorimetery and thermal 
imaging in a warm room and 
vehicle infusion
3.  Calorimetryand thermal 
imaging in a warm room and 
glucagon infusion
N=3 BAT negative:
No further PET/CT
Figure 1. Study visit summary. BAT, brown adipose tissue; 18F-FDG, 18F-fluorodeoxyglucose; PET, positron emission tomography.
1m from the subject. The subjects always sat fully upright in
the same chair, with head and arm rests maintained in the same
positions. Volunteers were asked to remain as still as possible,
with their shoulders held unrotated against the back of the chair
to minimize movement within the image frames during ther-
mal recordings. Immediately after the baseline thermal imaging
session, subjects were placed under the hood of the calorimeter
for the baseline RMR recording (for 15 min).
At t=−10min the infusion (vehicle or glucagon) was started
and, on the cold visit day, cold water was pumped through the
vest to begin the cooling process. The infusions were stopped
at t= 45min and the cold vest maintained for a further 45min.
Thermal imaging recordings were taken at baseline (Run A),
just after the start of the intervention (Run B), and the final
run (Run C) coincided with the end of infusion or cold vest
exposure. Immediately after, a final RMR measurement with
the hood calorimeter was also recorded (Figure S1A, B). Blood
samples were taken at t=−55,−10, 0, 10, 15, 30, 45 and 60min
(see below).
18F-FDG PET/CT Protocol
On arrival, peripheral venous cannulae were inserted in both
forearms. Volunteers wore light cotton trousers. After 30min
acclimation, at t=−75min, the cooling vest was put on and
cold water circulated through for 60min before the start of the
scan. The vest was later draped over the volunteers’ legs whilst
in the scanner. On the second visit (vehicle or glucagon infu-
sion) no cooling step was taken. At t=−10min the volunteers
entered the scanner and the infusion was started (ramped for
the first 10min, as previously described). Before the PET scan,
an anatomical CT scan of neck and thorax was performed. At
t= 0min, 180MBq of 18F-FDG was injected i.v. and a 60-min
dynamic emission scan was performed, with an axial field of
view frommandible tomid-thorax (Figure S1C). Blood samples
were taken at t=−55, −10, 0, 1, 3, 5, 10, 15, 30, 50 and 60min.
Blood Sampling
Samples for analysis of plasma glucagon were collected in
lithium heparin tubes containing 0.15ml aprotinin (Trasylol;
Bayer Schering Pharma, Berlin, Germany) and immediately
underwent centrifugation, after which plasma was promptly
separated and stored at −20 ∘C until analysis using a radioim-
munoassay [22]. Glucagon and glucose was measured at all
time points and catecholamines (plasma epinephrine and nore-
pinephrine) weremeasured on the start and end samples, by the
Department of Chemical Pathology, Imperial College Health-
care National Health Service Trust. Human fibroblast growth
factor (FGF)-21 levels in the start and end samples were mea-
sured using an enzyme-linked immunosorbent assay (Merck
Millipore, Darmstadt, Germany).
Image Analysis
For each subject, the second visit CT scan was non-linearly
registered and warped to the first visit CT scan using a
multi-resolution free-form deformation technique, measuring
the mutual information as a similarity measure between CTs.
The three-dimensional warp field estimate was subsequently
applied to the dynamic PET of the second visit. The adipose
tissue region of interest (ROI) was defined using tissue density
on CT (−150<Hounsfield Units<−5). A BAT ROI was then
defined as adipose tissue with an SUV of ≥2 on the cold scan.
Time–activity curves for BAT were generated by applying the
ROIs to the dynamic PET data from both visits. Arterial plasma
radioactivity was estimated using a whole-blood time–activity
curve derived from an aorta ROI scaled by the plasma to
blood ratio derived from the discrete blood samples. Using
the graphical Patlak model, estimates of the metabolic rate of
FDG were calculated. Finally, the metabolic rate of glucose
[MR(gluc)] was calculated by dividing the metabolic rate of
FDG by the lump constant (lump constant= 1.14) in adipose
2015 doi:10.1111/dom.12585 3
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Figure 2. Example positron emission tomography (PET)/CT images. Example CT (top row), PET (middle row) and fusion PET/CT (bottom row) images.
Column 1 is a subject who displays brown adipose tissue (BAT) activation during cold stimulation (one of the BAT positive cohort). Column 2 is of the
same subject as Column 1, but when he received glucagon infusion on his second scan. Column 3 is a different subject who also displayed BAT activation
on cold exposure, but showing his scan in response to vehicle in a warm room. Column 4 shows images from a volunteer who did not demonstrate BAT
activation during cold stimulation (one of the BAT negative cohort). PET images are average activity between 30 and 60 min normalized to injected dose
and body weight. HU, Hounsfield units; SUV, standardized uptake value.
tissue, [23] and multiplying by the concentration of glucose in
the plasma. Representative images are shown in Figure 2.
Thermal recordings taken with Flir Tools Plus software (Flir
Systems) were saved as stills every 30 s. Supraclavicular ROIs,
defined by a triangle limited by the acromioclavicular joint,
cricoid prominence and the sternoclavicular joint, were drawn
on the first image using Thermacam Pro software (Flir Sys-
tems) and repositioned on all subsequent stills from that run.
Data from each ROI were exported into Excel, where each cell
recorded a camera pixel temperature reading, and a macro was
created to calculate themean temperature of the top 10%hottest
pixels. Visual comparison of which pixels within the thermal
image ROI were being included in the temperature analysis (by
highlighting those falling into the top 10% of pixel tempera-
tures) confirmed in all cases that the hottest areas in the supr-
aclavicular ROI formed a contiguous cluster located on skin
overlying a depot of BAT (Figure 3). As a comparator (con-
trol) region, we also measured the temperature changes in an
ROI defined over the deltoid region for every thermal image.
The deltoid ROI (an area known to be devoid of underlying
BAT) was defined as a right-angled triangle extending from the
acromioclavicular joint to the lateral extremity of the deltoid.
Statistical Analysis
Based on previous studies of the hormonal and cold expo-
sure effects on human BAT activity [24,25], we calculated that,
for an equivalent rise in EE, a sample size of 4 per group
(glucagon versus control) would have 95% power to detect a
significant difference between the effects of cold exposure and
glucagon using 18F-FDG PET/CT in confirmed BAT-positive
volunteers. Because of safety considerations, as PET/CT scans
expose healthy patients in this study to ionising radiation, we
limited this study to males only and to the smallest possible
sample size to answer our initial question about the differential
effects of cold exposure and glucagon administration on human
BAT activity for a given rise in EE.
(A)
(B)
Figure 3. Examples of positron emission tomography (PET)/CT and ther-
mal images from the same subject at the end of a cooling vest visit. (A) Fused
18F-fluorodeoxyglucose (18F-FDG) PET/CT image (yellow areas represent
increasedmetabolic activity) of a brown adipose tissue (BAT)-positive sub-
ject during cold stimulation. (B)Thermal image taken at the end of the same
cold exposure from the same subject. The stars on the thermal image were
used to define the anatomical landmarks used, which defined the region of
interest for temperature analysis.
All data were analysed using GraphPad Prism 6 software
(GraphPad Software, Inc., San Diego, CA, USA). Results are
presented as means± standard error of the mean. One-way
repeated measures anova with Tukey’s test was used to
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Figure 4. Effects of cold exposure, vehicle infusion and glucagon infusion in a warm room on (A) energy expenditure (EE) and (B) metabolic rate of
glucose uptake [MR(gluc)] in brown adipose tissue (BAT) during 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT. RMR was
measured with an indirect calorimeter at the start and end of each intervention and the mean change from baseline are shown in (A). Baseline resting
EEs were as follows 1279± 59 kcal/day (cold), 1353± 52 kcal/day (vehicle) and 1315± 39 kcal/day (glucagon), and were not significantly different from one
another. Data are presented for all 11 volunteers (separated into BAT-positive and BAT-negative cohorts in Figure S4). (B) Shows MR(gluc) in BAT during
18F-FDG PET/CT determined under the same experimental conditions: cold exposure (blue bar), vehicle only (ambient temperature 23 ∘C) (red bar) and
glucagon infusion (green bar). Results are expressed as means± standard error of the mean, **p< 0.01, ***p< 0.001.
compare differences between the three intervention groups. A
p value< 0.05was considered to indicate statistical significance.
Results
Cold Exposure and Glucagon Infusion Produce a Similar
Acute Rise in Energy Expenditure in Adult Humans
Cold exposure with a cooling vest and 50 ng/kg/min
glucagon infusion cause a similar rise in RMR (∼14 and
15% from baseline, respectively) compared with vehicle:
193.0± 27.2 kcal/day with cold, 41.1± 70 kcal/day with vehi-
cle and 230.8± 30.1 kcal/day with glucagon (Figure 4A).
The baseline respiratory quotients (respiratory quotient:
Vco2/Vo2) in each group were not significantly different from
one another [0.797± 0.016 (cold); 0.788± 0.017 (vehicle); and
0.765± 0.021 (glucagon)] but rose significantly with glucagon
infusion [change from baseline in respiratory quotient by
end of intervention: −0.012± 0.009 (cold), −0.003± 0.001
(vehicle), and +0.055± 0.016 (glucagon, p< 0.01)], which was
indicative of the expected rise in rate of carbohydrate oxidation
with glucagon, in line with its glucose-liberating effects and
hence the relative substrate availabilities of glucose versus free
fatty acid, and consistent with our previous data [7,8]. Plasma
levels of glucagon rose only during the glucagon infusion,
which is shown in Figure S2 alongside plasma glucose and
insulin levels. Previous studies have suggested that glucagon
stimulates FGF-21 secretion in humans [26] and that FGF-21
stimulates BAT. We found a non-significant rise in circulating
FGF-21 levels in our cohort in response to glucagon infusion,
also detailed in Figure S2.
Circulating norepinephrine levels rose significantly with
cold exposure but not with vehicle or glucagon infusion
[cold 2.33± 0.14 to 2.84± 0.33mmol/L (p< 0.05), vehicle
1.95± 0.18 to 1.74± 0.18mmol/l and glucagon infusion
2.19± 0.18 to 2.02± 0.26mmol/l]. Circulating epinephrine
levels did not change (data not shown) in any group. Heart rate
and blood pressure data are presented in Figure S3. There was
a small rise in heart rate with glucagon infusion, consistent
with its well-described chronotropic effects. In comparison,
cold-induced peripheral vasoconstriction and hence a rise in
peripheral vascular resistance may account for the measured
rise in mean arterial pressure with cold exposure. In general,
these findings support the conclusion that for a similar rise in
RMR between glucagon infusion and cold exposure, glucagon
infusion induces less sympathetic outflow.
Cold Exposure but not Glucagon Infusion Activates Human
BAT Despite a Similar Rise in Energy Expenditure
We tested the hypothesis that the increased EE resulting from
acute glucagon administration to adult humans was mediated
by BAT activation using both 18F-FDG PET/CT and thermal
imaging.
18F-FDG PET/CT. In the eight subjects confirmed as having
active supraclavicular BAT deposits, BATmass ranged from 4.8
to 92.9 g, mean 36.7± 11.1 g. In our cohort of BAT-positive vol-
unteers, theMR(gluc) in BATwas significantly higher with cold
exposure than both vehicle and glucagon infusion. Although
there was a small trend in BAT activation after glucagon
infusion, there was no statistical difference in BAT MR(gluc)
between vehicle and glucagon infusion (Figure 4B): mean BAT
[MR(gluc)] with cold exposure 0.074± 0.007 μmol/kg/min,
vehicle 0.010± 0.003 μmol/kg/min and with glucagon
0.029± 0.008 μmol/kg/min. In line with this, a breakdown
of the EE rise between the BAT-positive and BAT-negative
groups (Figure S4) showed that the rise in EE induced by
glucagon in BAT-negative subjects was not less than that in the
BAT-positive group, confirming that glucagon has an effect on
RMR independent of BAT activity.
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(A)
(B) (C)
Figure 5. (A–C) Average supraclavicular region of interest temperature (∘C). Results are shown for baseline (Run A), mid-intervention (Run B) and end
intervention (Run C) for each visit type. Each run represents a 10-min thermal recording, with stills extracted every 30 s and an average reading of the upper
10% pixels calculated. These were then averaged across the cohort of brown adipose tissue (BAT)-positive [as defined on positron emission tomography
(PET)/CT; n= 8, hatched bars] and BAT-negative (n= 3, white bars). (A) Response to cold exposure (cooling vest). (B) Response to vehicle infusion in a
warm room. (C) Response to glucagon infusion in a warm room. Results are expressed as means± standard error of the mean, ***p< 0.001.
Thermal Imaging. All 11 subjects (eight BAT-positive and
three BAT-negative, as defined by their 18F-FDG PET/CT
characteristics on cold exposure, described above) also under-
went thermography of their neck during the three study visits
when calorimetry was performed (Figures 1 and S1A, B).
A rise in supraclavicular skin surface temperature has previ-
ously been shown to indicate underlying BAT thermogenic
activity [17,27]. In the BAT-positive group of eight, there was
a significant temperature rise in the neck with cold exposure,
with a mean increase in temperature between Run A (baseline)
and Run C (end exposure) of 0.44± 0.08 ∘C. In contrast, there
was no change in supraclavicular neck temperature with cold
exposure in the BAT-negative group (Figure 5A). These find-
ings confirm that thermal imagingwas able to identify indepen-
dently the same individuals who had cold-induced BAT activa-
tion as shown by 18F-FDG-PET/CT. In both the BAT-positive
and BAT-negative groups, thermal imaging showed no change
in neck temperature when subjects received either vehicle
(Figure 5B) or glucagon infusion (Figure 5C). As a comparator
(control) region, we plotted the temperature changes in an ROI
defined over the deltoid region (an area known to be devoid
of underlying BAT) for all of the thermal images (Figure S5).
All of the conditions (vehicle in a warm room, glucagon in a
warm room and cold exposure) were associated with a fall in
the skin temperature over the deltoid, as the experimental pro-
tocol required them to sit with the torso/shoulders exposed;
however, the fall in deltoid temperature in the vehicle and
glucagon visits was very similar (−1.05 and −1.09 ∘C respec-
tively) whereas the fall in temperature in response to the cold
exposure was much greater (−1.90 ∘C). These data suggest that
the rise in BAT-positive supraclavicular temperature with cold
exposure is even more pronounced (relative to the drop in skin
temperature elsewhere).
Taken together, these data show that cold exposure and
glucagon infusion cause a similar rise in EE, but only cold
exposure is associated with significant thermogenic activation
of BAT in the acute setting.
Discussion
This study is the first tomeasure the effects of glucagon infusion
on BAT activity in humans. We found that glucagon and cold
exposure induced a similar acute rise in EE in humans, but in
this setting only cold exposure, and not glucagon, induced the
activity of supraclavicular BAT in adult humansmeasuredusing
either 18F-FDG-PET/CT or thermal imaging. We also found
that, although cold exposure was capable of increasing sympa-
thetic activation (as determined by steady-state norepinephrine
levels), glucagon infusion did not significantly alter circulating
norepinephrine levels. These findings support the conclusion
that, whilst acute cold exposure and acute glucagon infusion
produce a very similar rise in RMR, the effector mechanisms
through which EE is elevated are different.These findings are of
importance to drug development based on glucagon receptor
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agonism, as the dose of glucagon used in the present study
increased EE significantly without sympathetic system activa-
tion, thus potentially avoiding the deleterious effects on the
cardiovascular system that have been encountered with some
weight-loss medications.
In 2009, metabolically active BAT in adult humans was
described in detail [10,11].This has led to a resurgence of inter-
est in the utility of BAT as a tantalizing target for safely increas-
ing EE to aid weight loss. Enhanced BAT activity may also
induce favourable effects on glucose homeostasis and circulat-
ing lipids [28]. Exposure to cold temperatures is themost potent
stimulator of BATmetabolic activity, which has been correlated
with the associated rise in EE that occurs in the cold [although
not so in this particular study (Figure S6)]. More recently, the
concept of repeated cold exposure as a means of recruiting
or upregulating BAT for therapeutic purposes has also been
reported [29], although the feasibility of such an approach in
a clinical setting remains to be seen. The effector mechanism
for cold-induced thermogenesis is the sympathetic nervous sys-
tem, which richly innervates BAT, via the 𝛽3 adrenoceptor. In
line with this, patients with catecholamine-secreting tumours
have evidence of increased BAT activity, which abates once
the tumour is removed, and thyrotoxic patients show a similar
upregulation of BAT activity, as thyroid hormone potentiates
𝛽-adrenergic signalling [25,30]. Conversely, a study very sim-
ilar to the present study described the effects of non-selective
𝛽-adrenergic stimulation by isoprenaline in healthy youngmen
on BAT activity. Vosselman et al. [24] found that, although iso-
prenaline infusion increased EE to the same extent as cold
exposure, it did not significantly activate BAT, indicating that
other tissues are responsible for generalized 𝛽-adrenergic ther-
mogenesis. Indeed, early preclinical trials of 𝛽3 agonists as
anti-obesity agents did not progress because of poor efficacy
[31]. A more recent study, using newer and more highly spe-
cific 𝛽3 agonists (licensed for other conditions), however, sug-
gests that pharmacological manipulation of BAT remains a
viable option. Cypess et al. [32] described significant BAT acti-
vation in response to a single dose of the selective 𝛽 ago-
nist mirabegron, associated with a 200 kcal/day rise in EE,
although this was not reported against the degree of measured
cold-induced BAT activity in the cohort. More recently, Broed-
ers et al. [33] described the effect of bile acids on human BAT
activation, reporting a small but significant rise in BATSUVmax,
from 1.0± 0.4 to 1.6± 0.4, compared with 7.2± 5.4 in acute
cold exposure. They therefore concluded that the maximum
achievable BAT activation in these subjects far exceeded the
effects of chenodeoxycholic acid, but that more potent bile acid
BAT activators may have traction as anti-obesity drugs.
18F-FDG-PET/CT, the imaging method chosen for all of
these BAT studies, is the currently accepted ‘gold standard’
method for measuring BAT volume and activity. In rodent
studies, thermographic measurement of BAT activity has been
validated against biochemical markers of BAT thermogenesis,
such as UCP-1 upregulation [34]. In human studies, Jang
et al. [17] reported that a temperature difference between the
neck and sternum of 0.9 ∘C had a positive predictive value of
85% for the presence of supraclavicular BAT, Symonds et al.
[18] recorded rises of 0.5 ∘C in supraclavicular temperature in
children after mild cold exposure, and Boon et al. [27] reported
a 0.4 ∘C cold-induced supraclavicular skin temperature rise,
which positively correlated with 18F-FDG-PET/CT quantifica-
tion of underlying BAT. In the present study all eight subjects
who had BAT activation after cold exposure as determined
by 18F-FDG-PET/CT also showed a rise in neck temperature,
as determined by thermal imaging during cold exposure,
although the correlation between PET-quantified BAT mass
and cold-induced neck temperature rise was not significant
in the present cohort (data not shown). We also observed that
the rise in neck temperature occurs within the first 10 min
after cold exposure and remains elevated for the duration of
the exposure. By contrast, the subjects with an absence of
cold-activated BAT activity on their PET/CT scan displayed no
change or a fall in neck temperature under cold conditions. In
all cases, both saline and glucagon infusions (in a warm room)
produced no rise in neck temperature on thermal imaging,
supporting the conclusion that glucagon produces at best only a
very modest effect on BAT activity in this experimental setting.
To further check the validity of our thermal findings, we
manually overlaid all thermal images on the corresponding
PET/CT images. In all eight BAT-positive subjects, the 10%
hottest pixels from the thermal image (that were used for
our data analysis) consistently formed a contiguous cluster
overlying the largest depot of BAT defined on that subject’s
corresponding PET/CT. Furthermore, when we analysed the
temperature change in the pixels that overlaid BAT on the
corresponding PET/CT, the same temperature rise was found
as produced by the (blinded) whole ROI analysis, confirming
that analysis of the entire ROI accurately reflected skin tem-
perature changes directly overlying a confirmed BAT depot.
In the three BAT-negative subjects, the 10% hottest pixels
were more sparsely distributed across the entire ROI. These
findings support the use of thermal imaging to investigate BAT
activity by directly measuring the output of the uncoupling
process, namely heat. Development of such novel methods
for quantifying and measuring the function of human BAT is
important, as the restoration or upregulation of BAT activity
in humans may provide a non-surgical means of treating
obesity. Indeed, although 18F-FDG PET/CT is still generally
regarded as the gold standard for measuring BAT activity,
the technique is expensive, exposes research participants to
ionizing radiation and may not be the best measure of BAT
metabolism as circulating glucose is used as a substrate for
BAT thermogenesis only after internal fatty acid stores and
then circulating free fatty acids have been used. Ouellet et al.
have reported on the utility of using other PET tracers, such
as 11C-acetate (to determine tissue oxidative activity) and
the fatty acid 18F-fluoro-thiaheptadecanoic acid (18FTHA) to
measure non-esterified fatty acid uptake in human BAT [35].
Others have focused on other methods of imaging without the
need for exposure to ionising radiation, such as fat-fraction
MRI to quantify BAT mass coupled with functional MRI to
investigate BAT activation, measuring blood flow as a marker
of thermogenesis [29].
The present work has important therapeutic implications.
Modern estimates suggest that BAT activity could account for
5% of the basal metabolic rate in humans [36], although its
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maximum inducible potential remains unknown. Two previ-
ous studies have reported on the addition of chronic glucagon
receptor agonism to the antidiabetic properties of GLP-1 recep-
tor agonism in diet-induced obese mice [5,6]. Co-agonism of
glucagon and GLP-1 receptors induced superior body weight
loss and improvements in glucose homeostasis than the GLP-1
receptor agonist alone, and caused a significant rise in EE.
These findings have led to intense interest in the concept of
balanced co-agonism of both the glucagon and GLP-1 recep-
tors to achieve superior weight loss as a result of the additional
EE effects of glucagon receptor activation. We confirmed the
applicability of this finding to humans, showing that glucagon
acutely increases EE in humans [7], and the present study builds
on our understanding of the mechanism by which it does so.
The dose of glucagon used in the present experiment was
based on our previous knowledge of the dose required to sig-
nificantly increase EE in humans. We have previously shown
that a dose of 50 ng/kg/min (i.e. 14 pmol/kg/min) i.v. glucagon
over 45 min increased resting EE significantly: by a mean
of 146.99 kcal/day in healthy overweight individuals [7]. This
dose, administered over 55min in the present study (notably on
a leaner and younger cohort) produced a 206.8± 29.6 kcal/day
rise in EE. In another recent publication, we showed that
a dose of 2.8 pmol/kg/min i.v. glucagon over 130min (i.e. a
fifth of the dose used in the present study but over twice the
time) produced a non-significant rise in EE of 66.8 kcal/day
in overweight volunteers (n= 13) [8]. The plateau plasma lev-
els measured in this experiment following glucagon infusion
(∼300 pM) are also consistent with those previous reports,
although higher than those typically expected when fasting
(∼50 pM); however, this would not be unexpected in the setting
of a pharmacological (weight-loss) agent containing a glucagon
agonist element. Notably, we have chosen to present our EE
data in units of kcal/day, thereby extrapolating our acute mea-
surement of EE rise with glucagon to the 24-h period. Whilst
there is strong animal data that chronic GLP-1 receptor and
glucagon-receptor co-agonism produces long-lasting weight
loss effects and increased EE, the effects of chronic glucagon
receptor agonism in humans are not known.Thus, whilst a 24-h
extrapolated value for the EE effects of glucagon infusion may
not necessarily be reflective of what would happen with pro-
longed glucagon agonism over that period (or longer), it gives
a sense of the potential therapeutic effect of this strategy.
We powered the present study to detect a significant differ-
ence between the effects of cold exposure and glucagon using
18F-FDG PET/CT in confirmed BAT-positive volunteers. With
the data presented in this study, we can confidently state that,
for the same rise in EE, glucagon has less effect on BAT than
cold, although it is not possible to exclude a small effect of
glucagon on human BAT activity with this study. Further-
more, although BAT activity was measured on PET/CT during
the 55min i.v. infusion of glucagon when plasma levels had
reached a plateau, cold exposure was initiated 1 h before the
scan, which may also have militated against detecting an effect
of glucagon on BAT activity. To reduce the contribution of
cold-activated BAT on the placebo or glucagon study days, we
maintained the scanner room temperature at 23 ∘C throughout
the study. Indeed, it would be interesting to further investigate
the interplay between constitutive BAT activity (as occurs in
mild cold stress) and its responsiveness to glucagon, which was
not answerable with this particular study. As we wished to limit
radiation exposure to women of childbearing potential, the
data presented are for young, healthy males only. Nevertheless,
our findings imply the existence of an as-yet unidentified, and
potentially targetable, glucagon-driven pathway to enhanced
EE. Other mechanisms by which glucagon may be exerting its
thermic effects have still to be explored in humans in greater
detail. Futile substrate cycling induced by non-physiological
glucagon receptor activation provides a means to increasing
the metabolic rate through stimulation of energy-consuming
cyclical metabolic pathways, with no net change in product
formation, in the liver and other tissues. Tracer studies have
indicated a significant effect on glucose cycling in response
to glucagon infusion, an effect that occurs predominantly at
low insulin levels and is abolished with high-dose insulin
infusion. The contribution of this to whole-body EE remains
to be adequately explored [37,38]. Glucagon also has well
described positive inotropic and chronotropic effects on the
myocardium, although the small contribution of the heart to
total RMR could not account for the rise in EE that we have
measured after glucagon infusion [39]. Finally, we have not
excluded a small element of BAT activation in humans in
response to glucagon administration, and the effects of chronic
glucagon receptor activation on BAT mass and function in
humans also remain unknown. In line with animal data, this
may include upregulation of classical BAT deposits versus
the possibility that chronic glucagon receptor agonism may
promote WAT transdifferentiation to a more brown-like phe-
notype. The present study has highlighted these important
areas for future research into the hormonal upregulation of
human EE as a safe therapeutic option for obesity.
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calorimetry and thermal imaging vist, warm room with vehicle
or glucagon infusion. (C) Timeline for PET/CT visit.
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